S taphylococcus aureus is the leading cause of infective endocarditis (IE) in industrialized countries. 1, 2 In fact, S aureus IE increased at a rate of 1.1% per quarter in the United States from 1999 to 2008. 1 This is problematic because S aureus IE is associated with more complications and higher mortality compared with IE due to other pathogens. 3-5 However, it remains unknown whether this finding persists when S aureus is compared with a non-S aureus cohort with similar baseline characteristics and if echocardiographic variables can identify patients with increased mortality in S aureus IE.
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Echocardiographic markers have been studied previously with respect to predicting outcome in IE with discordant results. For example, large or highly mobile vegetations have been studied as potential risk factors for embolic events and mortality. [6] [7] [8] Yet, studies report discordant results. Gotsman et al 8 found staphylococcal infection and vegetation size were independent predictors of embolic events and mortality, whereas Luaces et al 6 found vegetation size was independently associated with embolic events, but not mortality Similarly, the prognostic role of left ventricular size and systolic function in IE is incompletely defined. For example, Kiefer et al 9 found New York Heart Association (NYHA) Class III or IV heart failure was an independent predictor of 1-year mortality in the overall International Collaboration of Infective Endocarditis-Prospective Cohort Study (ICE-PCS) cohort. However, data for left ventricular ejection fraction (LVEF) and LV dimensions were not captured, yet may add incremental prognostic value in IE. Finally, inconsistencies exist about the causative pathogen and risk of tissue destruction, such as fistulas, perforation, or abscess formation. 10, 11 Using data from the ICE-PCS, 3 the main objectives of this study were to determine survival differences for left-sided native valve IE (LNVIE) between S aureus and non-S aureus IE and to identify echocardiographic predictors for adverse outcome in S aureus LNVIE.
Methods
Study Population
This study was approved by each site's Institutional Review Board or ethics committee. The inclusion criteria of ICE-PCS, a prospective, multicenter, international registry of IE have been reported previously. 3 Between January 2000 and September 2006, 5591 unique cases of Duke possible or Duke definite IE 12 were enrolled in ICE-PCS. Of these, 1379 comprised the Echo subset derived from 17 sites (9 countries, 3 continents), which prospectively enrolled an average of 81 subjects each. To be eligible for inclusion in ICE-Echo, a completed Echo-specific case report form (CRF) was required for each subject in addition to a completed baseline ICE-PCS CRF. Eligible sites must have completed Echo-specific CRFs on >50% of patients enrolled in ICE-PCS.
To ensure a homogeneous cohort with a comparable pathogenesis, only cases of LNVIE were included. Left-sided infection was defined as echocardiographic evidence of IE exclusively located on the aortic or mitral valves or structures in the left atrium or ventricle. Patients with right-sided IE or both right-and left-sided IE were excluded. Cases associated with any non-native valve or ring were defined as prosthetic and excluded. To evaluate the unique features of S aureus LNVIE, S aureus cases were examined and compared with non-S aureus cases.
To preserve the assumption of independence, only the first episode of LNVIE recorded for an individual patient was included in the analysis.
Clinical Data
Baseline characteristics were collected on the standard ICE-PCS CRF consisting of 275 variables. Data are stored in the ICE database and maintained by the Duke Clinical Research Institute.
Echocardiographic Data
Echocardiograms from the index hospitalization were performed as clinically indicated by expert investigators at each site, in accordance with applicable guidelines. For patients in ICE-Echo, echocardiograms were interpreted by a site expert echocardiographer using a standardized ICE-Echo CRF, consisting of 64 variables, including detailed information on left ventricular (LV) function and diameters, valvular status, vegetation characteristics and intracardiac complications. Echocardiographic data were obtained from a transthoracic echocardiogram or transesophageal echocardiogram. Echocardiographic data for the ICE-Echo cohort have been validated by an echocardiography core laboratory. 13 
Definitions
The definitions used in the ICE-PCS cohort have been described previously. 2 Briefly, definite vegetations were defined as irregularly shaped discrete echogenic masses adherent to, yet distinct from, cardiac surfaces, including valve structures, myocardium, and intracardiac devices. Vegetation size was measured as the maximal linear dimension. Vegetation size was analyzed both as a continuous variable and as a categorical variable using a cut-off value of 10 mm. Highly mobile vegetations were defined as oscillating vegetations remaining within the chamber or prolapsing between 2 chambers during a cardiac cycle. Intracardiac abscess was defined as thickened areas or masses within the myocardium or annular region with a nonhomogeneous echogenic or echolucent appearance. LV ejection fraction was assessed by visual estimate, rounded to the nearest 5%, whereas LV dimensions were obtained from either transthoracic parasternal long axis view or transesophageal transgastric long axis view.
Analytic Plan
The association between S aureus, echocardiographic variables and mortality was assessed. The primary outcomes were in-hospital and 1-year all-cause mortality. Continuous variables were presented as medians with 25th and 75th percentiles. Categorical variables were presented as frequencies and percentages of the specified group. Statistical significance was determined at the 0.05 level. All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC) and R for Mac OS X (Version 0.94.105, http:// www.R-project.org/).
Univariate and Multivariable Analysis
Univariate comparisons of clinical and echocardiographic characteristics were made with the Wilcoxon rank-sum test or the χ 2 test as appropriate. Bivariate logistic regression models were assessed to identify variables predictive of in-hospital and 1-year mortality. Risk estimates for in-hospital mortality are presented as odds ratios (ORs) and 95% confidence intervals (95% CI).
Multivariable logistic regression modeling was performed to determine the factors independently associated with S aureus infection among patients with LNVIE. This model included all clinical and echocardiographic variables considered a priori to be confounders or covariates of interest, including age (<45, 46-60, 61-70, and >70 years), sex, diabetes mellitus, hemodialysis, intravenous drug use, HIV, cancer, native valve predisposition to IE, time because first manifestation of disease, healthcare-associated IE, stroke, embolization, persistent bacteremia, congestive heart failure, persistent positive blood culture, any echocardiographic complication (abscess, fistula, or perforation), LVEF <40%, valvular regurgitation, and vegetation size. LVEF<40% was identified as a cut-off value because of potential alterations in management of subjects with heart failure and reduced LVEF. 14, 15 
Propensity-Matched Cohort
Because of differing baseline and echocardiographic characteristics between S aureus and non-S aureus groups, a propensity-matched cohort was developed. 16 The patients' probabilities of having S aureus as the causative organism, derived from the model described above, were used for matching non-S aureus LNVIE cases with S aureus LNVIE cases in a 1:1 ratio using Greedy next neighbor matching techniques. 17 
Cox Proportional Hazard Models With Inverse Probability of Treatment Weighting
To evaluate independent echocardiographic factors associated with mortality for S aureus IE, unique Cox Proportional hazard models were fitted for in-hospital and 1-year survival. The multivariate model included clinical and echocardiographic variables identified a priori by an experienced cardiologist. Moderate and severe mitral and aortic valve regurgitation were merged because of few events in each group.
To account for immortal time bias, surgery was modeled as a timedependent factor defined as days from admission to cardiac surgery during admission. These models were further weighted by the inverse probability of treatment weighting using a propensity score for surgery calculated individually. 19 The model included baseline variables and clinical characteristics considered associated with cardiac surgery. To address pathogen-specific predictors, a separate Cox model was performed for streptococcal IE, a cohort with a different disease course and prognosis. Similarly, both immortal time bias and treatment bias was taken into account.
Results
Baseline Clinical and Echocardiographic Features
A total of 1379 patients were included in the ICE-Echo cohort from January 2000 to September 2006. Of these, 727 cases with LNVIE (202 with S aureus and 525 without S aureus) met eligibility criteria for this study. Baseline clinical and echocardiographic characteristics of the overall study population are shown in Table 1 . Most comorbidities were significantly more common in patients with S aureus IE. However, those subjects with non-S aureus IE were more likely to have a history of a native valve predisposition (40% versus 24%; P<0.0001) and were more likely to undergo cardiac surgery during admission (55% versus 38%; P<0.0001) compared with those subjects with S aureus IE (Table 1) . Echocardiographic variables associated with non-S aureus IE were LV enlargement, moderate or severe aortic regurgitation, and vegetation presence and mobility (Table 1) . Mean vegetation size did not differ between groups (12 mm versus 13 mm; P=0.47).
Propensity-Matched Cohort
The propensity-matched cohort consisted of matched cases of S aureus LNVIE (n=187) and non-S aureus LNVIE (n=187). Fifteen cases of S aureus LNVIE were not included in the propensity-matched cohort because of random missing variables. Importantly, there were no significant differences in baseline characteristics in the matched S aureus LNVIE cohort (n=187) as compared with the overall S aureus LNVIE cohort (n=202). The matched non-S aureus LNVIE cohort included the following microorganisms: streptococci (n=77), enterococci (n=40), coagulase negative staphylococci (n=33), fungi (n=3), HACEK (n=1), Gram-negative (n=14), and culture negative (n=19) microorganisms.
Survival Data
In-hospital survival rates were significantly lower for S aureus than for non-S aureus in the overall LNVIE cohort (72% versus 88%, respectively; 95% CI, 0.08-0.23; P<0.0001), but not in the propensity-matched cohort (74% versus 79%, respectively; 95% CI, −0.04 to 0.14; P=0.26).
One-year survival rates were significantly lower for S aureus IE in both the overall cohort ( Figure 1A ; 57% versus 80%; 95% CI, 0.15-0.31; P<0.0001) and the propensity-matched cohort ( Figure 1B ; 59% versus 68%; P<0.05). Survival rates for matched non-S aureus IE were significantly lower than nonmatched non-S aureus IE in the LNVIE cohort ( Figure 1B ; 68% versus 86%; P<0.001). In a multivariate Cox proportional hazards model adjusted for age, sex, comorbidities, and echocardiographic variables, S aureus was independently associated with 1-year mortality in the overall, nonmatched cohort ( Figure 1C ). Furthermore, in a multivariate stratified Cox proportional hazards model adjusted for age, sex, comorbidities, and echocardiographic variables, S aureus remained independently associated with 1-year mortality in the propensity-matched cohort ( Figure 1D ).
Echocardiographic Predictors of Mortality in LNVIE
Echocardiographic data were obtained from a transthoracic echocardiogram in 59 of 202 cases (29%) and transesophageal echocardiogram in 143 of 202 cases (71%). In a bivariate logistic model for 202 cases of S aureus LNVIE adjusted for surgery, multiple variables were significantly associated with in-hospital or 1-year mortality ( Table 2 ). To evaluate independent echocardiographic variables associated with mortality for S aureus IE, unique Cox Proportional hazard models were made for in-hospital and 1-year survival. To account for both immortal time bias and treatment bias, surgery was both modeled as a time-dependent factor and included as a weight (Figure 2 ). When surgery was taken into account in the multivariate model, the risk of in-hospital mortality was 3× higher with the presence of LVEF<40% (OR, 3.01; 95% CI, 1.35-6.04) or an abscess (OR, 2.93; 95% CI, 1.52-5.42).
One-year mortality was 2× higher with the presence of mitral or aortic valve perforation (OR, 2.16; 95% CI, 1.21-3.68) or abscess (OR, 2.25; 95% CI, 1. 25-3.78 [15%]). The presence of a vegetation and vegetation size >10 mm were associated with in-hospital mortality in the bivariate models but did not predict mortality within the subset of S aureus IE in the multivariate models. Vegetation size, when assessed as a continuous variable, was also not independently predictive of mortality in S aureus IE.
Furthermore, to compare echocardiographic factors associated with mortality for microorganisms with varying pathogenesis, unique Cox Proportional hazard models with the same covariates as models for S aureus LNVIE were generated for 1-year survival in streptococcal IE only, as <10 in-hospital deaths occurred in streptococcal IE. Abscess formation was an (17) <0.0001
HIV positive 11 (5) 8 (2) <0.05
Current intravenous drug use 38 (18) 37 (7) <0.0001
Cancer 24 (12) 59 (11) 0.80
Native valve predisposition* 48 (24) 206 (40) <0.0001
Healthcare-associated IE 88 (45) 78 (16) <0.0001 Previous IE 7 (3) 25 (5) 0.54
Congenital heart disease 14 (7) 57 (11) 
Discussion
There are 2 major novel findings in this study. First, S aureus infection was identified as an independent predictor of late death in LNVIE, even when compared with a non-S aureus cohort matched by the likelihood of having S aureus infection from baseline characteristics. Second, in-hospital and 1-year prognostic echocardiographic variables for S aureus LNVIE were identified. Once accounting for survival bias and surgery, S aureus IE had a 3-fold higher risk of in-hospital mortality with the presence of LVEF<40% or abscess. One-year mortality was 2× higher with the presence of mitral or aortic valve perforation or abscess.
In the ICE-echo cohort, S aureus LNVIE was associated with more baseline comorbidities and complications as compared with other pathogens. S aureus IE was less likely to affect patients with pre-existing valvular disease as compared with non-S aureus LNVIE. These baseline differences between the S aureus and non-S aureus LNVIE cohorts are similar to those previously described in the overall ICE-PCS cohort, 2 as well as other studies. 20,21 Some baseline differences, such as increased ventricular dimensions and more moderate and severe aortic regurgitation in non-S aureus LNVIE may be due, in part, to the more acute onset of symptoms in S aureus LNVIE as compared with non-S aureus LNVIE.
S aureus LNVIE has higher mortality as compared with non-S aureus LNVIE. This finding is similar to previous studies with some important caveats. For example, our finding of increased mortality in S aureus as compared with non-S aureus is similar to a previous study by Hasbun et al 22 who identified that S aureus infection was independently associated with increased 6-month mortality (OR, 3.56; 95% CI, 1.54-6.79; P=0.004) in 75 cases of S aureus LNVIE from Connecticut. Although this study corroborates the findings of Hasbun et al, 22 some important distinctions should be noted. The current series is larger, prospectively collected, and international with a longer follow-up duration. Taken together, these distinctions attest to the generalizability of our results. Similarly, our finding is concordant with a European multicenter study that found that the presence of S aureus infection increased the relative risk of 1-year mortality significantly (RR, 1.9; 95% CI, 1. 16-3.14) in 384 Duke definite IE cases. 5 In the latter study, results were derived from multivariate models in heterogeneous cohorts, including native and prosthetic infections and right-and left-sided infections, whereas in this study, only LNVIE cases were included to ensure a homogenous cohort.
In addition, our study goes beyond others by generating a novel propensity-matched cohort. Interestingly, despite propensity matching for S aureus, S aureus remained independently associated with 1-year mortality. Of note, the propensity-matched non-S aureus cohort had significantly lower survival rates in comparison with the nonmatched, non-S aureus LNVIE cohort, indicating that when matching 1:1 with baseline characteristics similar to S aureus, cases of non-S aureus with the worst prognosis were selected. The remaining difference in outcome for the matched S aureus LNVIE cohort may, in part, reflect the increased virulence of S aureus.
In this study, we investigated whether echocardiographic markers could predict in-hospital and 1-year mortality in S aureus LNVIE. Our finding that large vegetations were not independently associated with an increased risk of mortality agreed with those of Luaces et al 6 who found that vegetation size was not independently associated with an increased risk of death, but not with others who found that vegetation size was an independent predictor of mortality. 5, 7, 8 Possible reasons why our results were not concordant with others were differing study designs (retrospective, single-center study 8 versus larger, prospective, multicenter, and international), multiple pathogens, 5, 7, 8 and different patient populations. 5, 8 An example, which highlights the pathogen and native valve-specific nature of our findings, is the study performed by Thuny et al. 5 Thuny et al 5 performed an elegant, prospective, multicenter analysis on 384 consecutive patients with IE from multiple pathogens to assess transesophageal echocardiographic characteristics associated with embolic events and death. In this study, vegetation length >15 mm was a predictor of 1-year mortality. Together with our findings, these data imply that the prognostic value of vegetation size for mortality may be pathogen and native/prosthetic valve specific. While heart failure, as a clinical diagnosis, is a major complication associated with adverse outcome in IE, 9, 23 correlation with LVEF may provide additive prognostic information. In this study, we identified LVEF<40% as an independent predictor of in-hospital death in S aureus LNVIE regardless of NYHA class status or valvular disease. Knowledge of patient LVEF may be useful because treatment strategies differ for subjects with LVEF<40% as compared with those with LVEF>40%. 24, 25 Extensive tissue destruction is an indication for early surgery in IE. 10 Even when surgery was accounted for in our multivariable model, the presence of an abscess was associated with in-hospital death and both valve perforation and abscess were associated with 1-year mortality in S aureus LNVIE and streptococcal LNVIE. The finding that perforation is an independent marker of mortality concurs with a study conducted by Bachour et al 11 who found that a valve perforation complicating LNVIE is associated with high mortality in a retrospective review of 123 LNVIE cases.
Abscess is a life-threatening complication that cannot be cured with antibiotic therapy alone. The association between extensive cardiac infection and adverse outcome may be related to uncontrolled infection or enhanced virulence of S aureus. Unfortunately, the design of this study does not allow for further clarification.
Other issues should be considered in the interpretation of these findings. Data quality was dependent on the accuracy and completeness of documentation and abstraction in ICE-PCS and ICE-Echo registries. Echocardiograms were performed as clinically indicated by expert investigators at each site in accordance with then applicable guidelines, thus transesophageal echocardiograms were only performed in addition to transthoracic echocardiography in 70% of S aureus LNVIE cases. Furthermore, variation in image quality and echocardiographic imaging systems did exist. The Core Laboratory validated echocardiographic data and did find substantial or almost perfect intra-and interobserver agreement for all echocardiographic variables. 13 Furthermore, some potential confounders, such as heart failure status and cardiac complications had missing data. Nonetheless, distribution of missing values was scrutinized and occurred at random as previously described. 19 Furthermore, this was a PCS, and observed differences in survival between S aureus and non-S aureus LNVIE may have resulted from residual and unmeasured confounding. However, we were able to match cohorts by several robust baseline characteristics. Finally, cases of LNVIE were reported from hospitals within each region that are referral centers with cardiac surgery programs. Therefore, the results 
Conclusions
S aureus infection is an independent predictor of 1-year mortality in subjects with LNVIE. When surgery and clinically prognostic indicators were taken into account, intracardiac abscess and LVEF<40% independently predicted in-hospital mortality in S aureus LNVIE. Furthermore, intracardiac abscess and valve perforation independently predicted 1-year mortality in S aureus LNVIE. Ideally, identifying these independent echocardiographic markers should lead to more aggressive patient management in patients with S aureus LNVIE. Future research on microorganism and host-specific factors is desirable to better elucidate the virulence of S aureus bacteremia in LNVIE. 
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